Basic Science Research
The basic science research laboratories of the Department of Dermatology are located near the Duke Dermatology clinic and the Levine Science Research Center. Our research interests are directed to address skin diseases of connective tissue, epithelial tissue and dermatological immune disorders. We use cutting edge technologies to tackle specific questions at the genetic, epigenetic and protein levels.
The laboratory of Dermatoimmunology is under the direction of Dr. Russell Hall. This laboratory is interested in the pathophysiology and molecular biology of the blistering diseases including dermatitis herpetiformis, cicatricial pemphigoid, and bullous pemphigoid and pemphigus. Studies are currently underway characterizing the mucosal immune response in patients with dermatitis herpetiformis including the patterns of cytokine and inflammatory cell activation in the skin, gut and circulation that occur in response to ingestion of wheat protein. Dr. Hall's laboratory is also investigating the pathogenesis of the auto-immune blistering diseases bullous pemphigoid and pemphigus vulgaris. These studies are directed at understand the antigenic specificity of auto-antibodies and correlation with clinical disease activity and understanding the role of B cells in the generation and maintenance of auto-antibodies. Mechanistic studies that are linked to clinical trials utilizing new therapies including rituxan and infliximab in the treatment of these diseases are ongoing.
The laboratory of Epithelial Biology and Skin Cancer Biology is under the direction of Dr. Jennifer Zhang. This laboratory uses monolayer cell culture, regenerated human skin and mouse genetic models to study 1) genetic regulatory mechanisms governing epithelial proliferation and differentiation and 2) signaling networks important for nonmelanoma and melanoma skin cancer.
The research laboratory of Dr. Chuan-Yuan Li is roughly divided into three areas: tumor response to therapy, with a special emphasis on skin cancer such as melanoma and squamous cell carcinoma where current treatment outcomes are dismal; stem cell and regenerative medicine where research is conducted to investigate novel mechanisms of stem cell biology so that knowledge gained can be translated into regenerative medicine; and finally the mechanisms of carcinogenesis, with emphasis on skin cancers, so that better strategies could be devised to prevent and treat these cancers.
The laboratory of Dr. Terry Lechler is studying the morphogenesis of epithelia in the skin and intestine, two highly proliferative tissues, with focus on spindle orientation/asymmetric cell division in the epidermis, regulation of centrosomes and microtubule organization, and cell-cell adhesion. The lab studies the cell biology of how mitotic spindle positioning is controlled, how these divisions are regulated developmentally and the consequences of loss of spindle orientation on tissue development, homeostasis and regeneration. The lab is also studying both how centrosomal and non-centrosomal microtubule arrays are formed in cells, using genetics to understand the functions of these arrays, and determining how differentiation signals impact the composition and function of centrosomes and microtubules. Finally, the lab studys cell adhesion structures including adherens junctions, tight junctions and desmosomes and their interplay with underlying cytoskeletal structures.
The laboratory of Dr. Amanda MacLeod investigates surveillance and repair function in the skin, focusing on immune regulation and modulation during skin injury, infection, and cancer. The lab identifies and characterizes key factors that regulare innate and adaptive immunity in the skin by using interdisciplinary approaches including molecular and cellular biology, and human and murine wound, infection and inflammation model systems to study how host factors drive skin barrier immunity. Also, the lab's goal is to define immune surveillance and escape mechanisms present in the human cutaneous squamous cell carcinoma (SCC) microenvironment to ultimately identify novel targets for immunotherapy.